A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

November 23, 2026

Study Completion Date

March 23, 2027

Conditions

Breast Cancer

Interventions

DRUG

Elacestrant

Patients will receive elacestrant 345 mg/daily administered orally for 4 weeks.

DRUG

Leuprorelin

Patients randomized in arm B will recieve Leuprorelin at Day 1 and Day 29

Trial Locations (1)

Gustave Roussy, Villejuif